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Abstract
We analyzed p53 mutations in 17 N-butyl-N-(4-hydroxybutyl) nitrosamine-induced bladder transitional cell carcinomas
(TCCs) with or without areas of squamous cell carcinoma (SCC) of Long–Evans Cinnamon (LEC) and F344 rats, and in 7 N-
methyl-N-nitrosourea-induced colon adenocarcinomas of LEC rats by polymerase chain reaction-single strand conformation
polymorphism analysis and DNA sequencing. Of these bladder tumors, one TCC with moderately differentiated SCC had a T
to G transversion mutation at codon 141, leading to a Val to Gly amino acid change. No p53 mutation was found in colon
adenocarcinomas. Thus a p53 gene mutation seems infrequent in these rat bladder and colon carcinogenesis models even in
the late stage. Ó 1997 Elsevier Science Ireland Ltd.
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1. Introduction
Carcinogenesis is a multistep process which
involves the accumulation of gene alterations [1–3].
Inactivation of the p53 tumor suppressor gene is one
of the most common genetic alterations in many
human cancers including lung, breast, urinary bladder
and colon cancers [4,5]. It has been reported that the
frequency of p53 mutation is approximately 30–60%
in human urinary bladder cancer [6–8], and 50–75%
in colon cancer [4,9,10], especially in the late stage.
Hepatocellular carcinomas (HCCs) in China and
southern Africa are known to have a specific G to T
transversion in codon 249 of the p53 gene [11–13],
and this mutation is thought to be correlated with
exposure to aflatoxins. Animal studies have shown
that some carcinogens, such as alkylating N-nitroso
compounds, induce a specific gene alteration. For
example, N-methyl-N-nitrosourea specifically induces
a G to A transition at the second nucleotide of codon
12 in the Ha-ras gene in various organs of different
animals [14], as a result of O6-methylguanine DNA
adduct formation [15].
The LEC rat, a model of human Wilson’s disease,
develops liver [16] and kidney [17] tumors sponta-
neously by copper accumulation in these organs
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[18]. In this study, we screened the p53 gene mutation
in exons 2–9 and a part of exon 10 in carcinogen-
induced rat bladder and colon tumors of LEC and
F344 rats by the PCR-SSCP method.
2. Materials and methods
2.1. Animal experiments
Seven-week-old male LEC (n = 3) and F344
(n = 7) rats were given 0.1% BBN in their drinking
water every other week from week 0–11, and then
0.05% BBN every other week from week 32–43,
and were killed in week 50 to obtain bladder tumors
(Fig. 1). Six-week-old male LEC rats (n = 7) were
injected i.p. with MNU (50 mg/kg body weight)
once a week for 6 weeks and killed in week 24 to
obtain colon tumors. Seventeen bladder tumors (3–
20 mm in size) and 7 colon tumors (4–8 mm in
size) were examined. Parts of the tumors were frozen
in liquid nitrogen and kept at - 80 ° C until use. The
remaining portions of the tumors were fixed in 10%
buffered formalin for histological examination.
2.2. DNA extraction
High molecular weight DNA was prepared from
tumor tissues by proteinase K digestion and phenol/
chloroform extraction [19].
Fig. 1. Experimental design to induce bladder and colon tumors.
Fig. 2. Schematic presentation of the locations of PCR primers to analyze p53 mutations.
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2.3. Oligonucleotide PCR primers
Nine pairs of primers flanking exons 2–9 and a
part of exon 10 of the p53 gene were synthesized in
a Model 392 DNA synthesizer (Perkin-Elmer, Nor-
walk, CT). All primers except an antisense primer
for exon 10 were those of intron sequences to avoid
amplification of pseudogenes [20] (Fig. 2). The nu-
cleotide sequences of primers are summarized in
Table 1.
2.4. PCR-SSCP analysis
PCR-SSCP analysis was performed by the method
of Orita et al. [21] with a minor modification. Samples
of 5 ml of the PCR mixture contained 50 ng of geno-
mic DNA as a template, 5 pmol each of primers, 0.125
nmol each of dNTPs, 0.25 ml of [a-32P]dCTP (110
TBq/mmol; 370 MBq/ml) and 0.25 units of Taq
DNA polymerase (Takara, Ohtsu, Japan) in the buffer
supplied by Takara. Thirty cycles of the reaction at
94, 55 and 72 ° C each for 1 min were carried out in
a thermal cycler (GeneAmpy PCR System 9600,
Perkin-Elmer). The resultant PCR product was
mixed with 245 ml of a formamide dye mixture
(95% for-mamide, 20 mM EDTA, 0.05% xylene cya-
nol and 0.05% bromophenol blue) and heated at 95° C
for 3 min for denaturation. Then 1 ml of the mixture
was applied to 6% polyacrylamide gel containing 45
mM Tris–borate (pH 8.3) and 1 mM EDTA. All PCR
products were analyzed by PCR-SSCP at glycerol
concentrations of 0, 5 or 10%, respectively. Electro-
phoresis was performed at 15 W for 3–5 h with cool-
ing by a fan at room temperature. The gel was dried on
filter paper and exposed to an X-ray film with an
intensifying screen overnight at - 80 ° C. In each case,
the mobility shift on PCR-SSCP analysis was repro-
ducible.
2.5. DNA sequencing
The portion of the dried polyacrylamide gel con-
taining DNA with abnormal mobility found on SSCP
analysis was cut out and DNA was extracted over-
night from the gel with 50 ml of water at 37 ° C.
DNA fragments re-amplified by PCR with the
extracted DNAs as templates and the same primers
as used in the original PCR were subcloned into TA
vectors with the original TA cloningy Kit (Invitro-
gen, San Diego, CA). Eight individual clones of each
sample with a mobility shift were sequenced by the
fluorescence-based dideoxy sequencing method with
a DNA sequencer (Model 377, Perkin-Elmer).
Table 1
Oligonucleotide primers used for p53 gene analysis
Name Sequence
P2-1 5¢ -CAGTACACAGATGTTCTCTC-3 ¢
P2-2 5¢ -CAGGGGCCCTGTAAGATCCA-3¢
P3-1 5¢ -GCCTGGGGTAAGTGAGATTC-3 ¢
P3-2 5¢ -TAAGTCCCCTCTTGCCCGGC-3¢
P4-1 5¢ -GTTCTTCTTTGGCCCATCCA-3¢
P4-2 5¢ -AAGCAACTCTTCAGGCCCAC-3¢
P5-1 5¢ -GATTCTTTCTCCTCTCCTAC-3¢
P5-2 5¢ -ACAGGCAGTGCCAGTGCTCA-3¢
P6-1 5¢ -CCCGGCCTCTGACTTATTCT-3 ¢
P6-2 5¢ -CCCAACCTGGCACACAGCTT-3¢
P7-1 5¢ -CTGTGCCTCCTCTTGTCCCG-3¢
P7-2 5¢ -CTCCACCTTCTTTGTCCTGC-3¢
P8-1 5¢ -AAAGTCACCCCTTGCTCTCT-3 ¢
P8-2 5¢ -TAATCCAATAATAACCTTGG-3¢
P9-1 5¢ -TGTCCTACTTCATCCTTGCT-3¢
P9-2 5¢ -AGGCGCTGCCCCAGGTCACT-3 ¢
P10-1 5¢ -CCCTCCCTTTTCTGTATTCC-3¢
P10-2 5¢ -CAGCAGAGACCCAGCAACTA-3¢
Table 2
A p53 mutation in BBN-induced bladder tumors and MNU-induced colon tumors
Histology of the tumors No. of samples p53 mutation
Incidence Codon Nucleotide and amino
acid change
Bladder TCC 10 0 –
TCC with SCC 7 1 141 GTG (Val) fi GGG
(Gly)
Colon Adenocarcinoma 7 0 –
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3. Results
Data are summarized in Table 2. Bladder tumors
from 3 LEC and 7 F344 rats included 10 pure TCCs
and 7 TCCs with areas of well to moderately differ-
entiated SCC histologically. On PCR-SSCP analysis
of DNA samples extracted from these bladder tumors,
a band shift of exon 5 was detected in one tumor of an
LEC rat (Fig. 3). Sequence analysis showed a T to G
transversion mutation in codon 141, leading to a Val
(GTG) to Gly (GGG) amino acid change (Fig. 4). This
bladder tumor was identified as a TCC with areas of
moderately differentiated SCC, and its histological
grade of malignancy was the highest among the blad-
der tumors examined (Fig. 5).
All colon tumors of LEC rats were adenocarcin-
omas invading the submucosa and subserosa. We
did not detect any p53 mutations in these colon
tumors.
4. Discussion
p53 mutations generally occur within exons 5–8 in
human cancers [4,5]. To test whether different hot-
spots of the p53 gene exist in rodents, we screened
all coding regions of the rat p53 gene except a part of
exon 10. In the present study, we found a mutation in
exon 5, but its frequency was lower than that reported
in human bladder or colon cancer. Possible reasons for
the low incidence of the p53 mutation in rats are (a) in
spite of the large size of their tumors and the presence
of areas of SCC the stage of tumors in rats is earlier
than that in humans because usually no metastases are
observed in animals with carcinogen-induced bladder
Fig. 3. Results of PCR-SSCP analysis of the p53 gene exon 5 in
BBN-induced rat bladder tumors. A shifted band was observed in a
TCC with moderately differentiated SCC in an LEC rat (arrow-
head).
Fig. 4. DNA sequences in samples of bladder tumors. GTG (Val) to GGG (Gly) transversion at codon 141 of the p53 gene is shown.
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tumors and (b) there may be a species difference in the
incidence of p53 mutations.
It is reported that the incidence of p53 gene muta-
tions in BBN-induced bladder tumors in F344 rats is
30–67% [22,23], and that in N-[4-(5-nitro-2-furyl)-2-
thiazolyl] formamide-induced tumors in F344 rats is
0–7% [24,25]. In our study, we detected a p53 muta-
tion in 6% (1/17) of BBN-induced bladder tumors.
One factor for this discrepancy in incidence might
be a difference in the period of administration of car-
cinogens, the period of administration of BBN in our
study being shorter than that in the study of Masui et
al. [22,23]. The GTG (Val) to GGG (Gly) mutation in
codon 141 detected in the present study has been
observed in BBN-induced small TCC [22] in addition
to T fi G mutations in other codons [5,7,22].
Although G fi A and G fi T mutations are common
in the p53 gene, a T fi G mutation is rare in human
cancers [5].
In a recent study, we did not find a p53 mutation
in spontaneously developed HCCs in LEC rats,
but found it in diethylnitrosamine or N-ethyl-N-hy-
droxyethyl-nitrosamine-induced HCCs (unpublished
data). Nagao et al. [26] reported that all Apc gene
mutations in rat colon tumors induced by 2-amino-
1-methyl-6-phenylimidazo [4,5-b]pyridine, a hetero-
cyclic amine, were specific GGGA to GGA frameshift
mutations in various codons due to deletion of G, but
they found no p53 mutations [27]. Animal models
provide opportunities for studies on carcinogen-spe-
cific or organ-specific mutations. As the database on
mutations in laboratory animals is limited, more stu-
dies on these mutations induced by various carcino-
gens are necessary.
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